Comparative Pharmacology
Head-to-head clinical analysis: CYCLOPAR versus PARAFON FORTE DSC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOPAR versus PARAFON FORTE DSC.
CYCLOPAR vs PARAFON FORTE DSC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclopar (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Chlorzoxazone acts on the central nervous system (CNS) at the spinal cord level, possibly by depressing polysynaptic reflexes, producing skeletal muscle relaxation without affecting neuromuscular transmission.
500 mg orally twice daily for 7-14 days.
Adults: 4 g (500 mg x 8 tablets) orally every 6-8 hours as needed; maximum 8 g (16 tablets) per 24 hours.
None Documented
None Documented
4-6 hours in normal renal function; prolonged to 12-24 hours in moderate impairment; up to 48 hours in severe impairment
1-3 hours (terminal); clinically relevant for dosing intervals of 4-6 hours.
Renal (80-90% unchanged), fecal (10-20%)
Primarily renal (85-95% as glucuronide conjugates and unchanged drug; <5% fecal).
Category C
Category C
Muscle Relaxant
Muscle Relaxant/Analgesic Combination